AU2013255441B2 - Substituted pyrazole compounds as CRAC modulators - Google Patents

Substituted pyrazole compounds as CRAC modulators Download PDF

Info

Publication number
AU2013255441B2
AU2013255441B2 AU2013255441A AU2013255441A AU2013255441B2 AU 2013255441 B2 AU2013255441 B2 AU 2013255441B2 AU 2013255441 A AU2013255441 A AU 2013255441A AU 2013255441 A AU2013255441 A AU 2013255441A AU 2013255441 B2 AU2013255441 B2 AU 2013255441B2
Authority
AU
Australia
Prior art keywords
methyl
pyridin
substituted
pyrazol
trifluoromethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
AU2013255441A
Other languages
English (en)
Other versions
AU2013255441A1 (en
Inventor
Gokul Keruji Deshmukh
Nageswara Rao Irlapati
Rajender Kumar Kamboj
Nilesh Raghunath Khedkar
Kiran Chandrashekhar Kulkarni
Venkata P. Palle
Zubair Abdul Wajid Shaikh
Neelima Sinha
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lupin Ltd
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of AU2013255441A1 publication Critical patent/AU2013255441A1/en
Application granted granted Critical
Publication of AU2013255441B2 publication Critical patent/AU2013255441B2/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2013255441A 2012-05-02 2013-05-01 Substituted pyrazole compounds as CRAC modulators Expired - Fee Related AU2013255441B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN6/KOL/2012 2012-05-02
IN6KO2012 2012-05-02
IN1474/KOL/2012 2012-12-28
IN1474KO2012 2012-12-28
PCT/IB2013/053446 WO2013164773A1 (en) 2012-05-02 2013-05-01 Substituted pyrazole compounds as crac modulators

Publications (2)

Publication Number Publication Date
AU2013255441A1 AU2013255441A1 (en) 2014-11-13
AU2013255441B2 true AU2013255441B2 (en) 2017-11-09

Family

ID=48428566

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013255441A Expired - Fee Related AU2013255441B2 (en) 2012-05-02 2013-05-01 Substituted pyrazole compounds as CRAC modulators

Country Status (7)

Country Link
US (2) US9409898B2 (enExample)
EP (1) EP2844656A1 (enExample)
AU (1) AU2013255441B2 (enExample)
CA (1) CA2871222A1 (enExample)
IN (1) IN2014MN02127A (enExample)
WO (1) WO2013164773A1 (enExample)
ZA (1) ZA201407668B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015197187A1 (en) * 2014-06-24 2015-12-30 Grünenthal GmbH Pyrazolyl-based carboxamides v
WO2015197188A1 (en) * 2014-06-24 2015-12-30 Grünenthal GmbH Pyrazolyl-based carboxamides as crac inhibitors
WO2016187182A1 (en) 2015-05-18 2016-11-24 Beth Israel Deaconess Medical Center, Inc. Substance p, mast cell degranulation inhibitors, and peripheral neuropathy
CN113557020A (zh) 2018-09-14 2021-10-26 瑞真药业公司 包含crac抑制剂和皮质类固醇的组合物及其使用方法
EP3886854A4 (en) 2018-11-30 2022-07-06 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
MX2021014864A (es) 2019-06-06 2022-01-18 Basf Se N-(pirid-3-il)carboxamidas fungicidas.
CN110604735B (zh) * 2019-09-18 2022-10-25 华东师范大学 一种治疗肝纤维化、硬皮病的化合物及其应用
WO2021063735A1 (en) 2019-10-02 2021-04-08 Basf Se New bicyclic pyridine derivatives

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999051580A1 (en) * 1998-04-08 1999-10-14 Abbott Laboratories Pyrazole inhibitors of cytokine production

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU751139B2 (en) * 1997-10-13 2002-08-08 Astellas Pharma Inc. Amide derivative
CA2332957A1 (en) * 1998-06-05 1999-12-09 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted 1-(4-aminophenyl)pyrazoles and their use as anti-inflammatory agents
EP1653968A4 (en) 2003-07-23 2006-09-06 Synta Pharmaceuticals Corp METHOD FOR MODULATING CALCIUMION RELIEF ACTIVATED CALCIUMION CHANNELS
CN101083985A (zh) 2004-09-21 2007-12-05 幸讬制药公司 用于炎症及免疫相关用途的化合物
MX2007008290A (es) 2005-01-07 2008-02-15 Synta Pharmaceuticals Corp Compuestos para inflamacion y usos inmuno-relacionados.
WO2006081389A1 (en) 2005-01-25 2006-08-03 Synta Pharmaceuticals Corp. Thiophene compounds for inflammation and immune-related uses
US8518950B2 (en) 2005-01-25 2013-08-27 Synta Pharmaceuticals Corp. 2-amido pyrazines for inflammation and immune related uses
CA2639913A1 (en) 2006-01-25 2007-08-02 Synta Pharmaceutical Corp. Phenyl and pyridyl compounds for inflammation and immune-related uses
CA2640090A1 (en) 2006-01-25 2007-08-02 Synta Pharmaceuticals Corp. Substituted aromatic compounds for inflammation and immune-related uses
WO2007087442A2 (en) 2006-01-25 2007-08-02 Synta Pharmaceuticals Corp. Substituted biaryl compounds for inflammation and immune-related uses
DK1984338T3 (da) 2006-01-31 2013-04-22 Synta Pharmaceuticals Corp Pyridylphenylforbindelser til inflammations- og immunrelaterede anvendelser
CA2695148A1 (en) 2007-08-01 2009-02-05 Synta Pharmaceuticals Corp. Pyridine compounds for inflammation and immune-related uses
JP5411141B2 (ja) 2007-09-10 2014-02-12 カルシメディカ，インク． 細胞内カルシウムを調節する化合物
US8389567B2 (en) 2007-12-12 2013-03-05 Calcimedica, Inc. Compounds that modulate intracellular calcium
CA2734500A1 (en) 2008-08-27 2010-03-11 Calcimedica Inc. Compounds that modulate intracellular calcium
US8524763B2 (en) 2008-09-22 2013-09-03 Calcimedica, Inc. Inhibitors of store operated calcium release
CA2739303A1 (en) 2008-10-01 2010-04-08 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
US8618307B2 (en) 2009-09-16 2013-12-31 Calcimedica, Inc. Compounds that modulate intracellular calcium
US8377970B2 (en) 2009-10-08 2013-02-19 Rhizen Pharmaceuticals Sa Modulators of calcium release-activated calcium channel
EP2606033A1 (de) 2010-08-20 2013-06-26 Grünenthal GmbH Substituierte cyclische carboxamid- und harnstoff-derivate als liganden des vanilloid-rezeptors
JP5387541B2 (ja) 2010-10-29 2014-01-15 住友電装株式会社 グロメット
PL2632906T3 (pl) * 2010-10-30 2016-09-30 Oksazolinowe i izoksazolinowe pochodne jako modulatory kanałów typu CRAC
CA2816769A1 (en) 2010-11-10 2012-05-18 Gruenenthal Gmbh Substituted heteroaromatic carboxamide and urea derivatives as vanilloid receptor ligands
EP2704701B1 (en) 2011-05-03 2018-01-03 PRCL Research Inc. Compounds for inflammation and immune-related uses
AU2012325901A1 (en) 2011-10-19 2014-05-15 Calcimedica, Inc. Compounds that modulate intracellular calcium
US9856240B2 (en) 2011-10-19 2018-01-02 Calcimedica, Inc. Compounds that modulate intracellular calcium

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999051580A1 (en) * 1998-04-08 1999-10-14 Abbott Laboratories Pyrazole inhibitors of cytokine production

Also Published As

Publication number Publication date
WO2013164773A1 (en) 2013-11-07
US20160304507A1 (en) 2016-10-20
AU2013255441A1 (en) 2014-11-13
IN2014MN02127A (enExample) 2015-09-11
US9409898B2 (en) 2016-08-09
EP2844656A1 (en) 2015-03-11
US20150111925A1 (en) 2015-04-23
ZA201407668B (en) 2015-11-25
CA2871222A1 (en) 2013-11-07

Similar Documents

Publication Publication Date Title
US9399638B2 (en) Substituted pyridine compounds as CRAC modulators
US9409898B2 (en) Substituted pyrazole compounds as CRAC modulators
ES2605388T3 (es) Compuesto inhibidor de Trk
US9725463B2 (en) Substituted heterocyclic compounds as CRAC modulators
US9790231B2 (en) Chromane and chromene derivatives and their use as CRAC modulators
DK2632906T3 (en) Oxazoline and isoxazolines AS CRACMODULATORER
MX2011000738A (es) 3,4-diarilpirazoles como inhibidoers de proteina cinasa.
CA2695304A1 (en) Pyrimidine and pyridine derivatives and their pharmaceutical use and compositions
CA3090445A1 (en) Substituted pyrazoles ffa4/gpr120 receptor agonists
US7781460B2 (en) Substituted indazoles as inhibitors of phosphodiesterase type-IV
HK1227858A1 (en) Oxazoline and isoxazoline derivatives as crac modulators
HK1187918B (en) Oxazoline and isoxazoline derivatives as crac modulators

Legal Events

Date Code Title Description
MK25 Application lapsed reg. 22.2i(2) - failure to pay acceptance fee